Rocket Pharmaceuticals Inc (RCKT) — Cash Flow-to-Debt Ratio
Rocket Pharmaceuticals Inc (RCKT) has a Cash Flow-to-Debt Ratio of -0.73x as of June 2026, meaning its operating cash flow of $-39.61 Million could theoretically repay -1% of its total liabilities ($54.27 Million) in one year. See Rocket Pharmaceuticals Inc (RCKT) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Rocket Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Rocket Pharmaceuticals Inc across 14 annual periods. For the full cash flow conversion analysis, see RCKT cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Rocket Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Rocket Pharmaceuticals Inc. Check how high is Rocket Pharmaceuticals Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.57x | $-190.01 Million | $53.23 Million | ▼ -9.7% |
| 2024 | -3.25x | $-209.72 Million | $64.47 Million | ▼ -23.1% |
| 2023 | -2.64x | $-194.92 Million | $73.77 Million | ▲ +7.9% |
| 2022 | -2.87x | $-178.14 Million | $62.12 Million | ▼ -0.1% |
| 2021 | -2.86x | $-121.16 Million | $42.30 Million | ▼ -235.1% |
| 2020 | -0.85x | $-74.64 Million | $87.31 Million | ▲ +14.3% |
| 2019 | -1.00x | $-64.66 Million | $64.82 Million | ▼ -6.2% |
| 2018 | -0.94x | $-53.79 Million | $57.28 Million | ▼ -94.3% |
| 2017 | -0.48x | $-26.11 Million | $54.01 Million | ▲ +26.7% |
| 2016 | -0.66x | $-37.27 Million | $56.48 Million | ▲ +82.9% |
| 2015 | -3.86x | $-17.42 Million | $4.51 Million | ▼ -2163.3% |
| 2014 | -0.17x | $-9.74 Million | $57.08 Million | ▼ -36.9% |
| 2013 | -0.12x | $-6.46 Million | $51.76 Million | ▲ +41.8% |
| 2012 | -0.21x | $-6.94 Million | $32.35 Million | — |